5 Stocks Raising The Health Services Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 49 points (0.3%) at 16,147 as of Friday, Nov. 29, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 1,869 issues advancing vs. 987 declining with 109 unchanged.

The Health Services industry currently sits up 0.3% versus the S&P 500, which is up 0.3%. Top gainers within the industry include Opko Health ( OPK), up 2.3%, and Smith & Nephew ( SNN), up 0.7%. On the negative front, top decliners within the industry include Boston Scientific ( BSX), down 0.7%, Grifols ( GRFS), down 0.6% and Quest Diagnostics ( DGX), down 0.5%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Fresenius Medical Care AG & Co. KGaA ( FMS) is one of the companies pushing the Health Services industry higher today. As of noon trading, Fresenius Medical Care AG & Co. KGaA is up $0.25 (0.7%) to $35.01 on light volume. Thus far, 19,451 shares of Fresenius Medical Care AG & Co. KGaA exchanged hands as compared to its average daily volume of 137,800 shares. The stock has ranged in price between $34.69-$35.06 after having opened the day at $34.74 as compared to the previous trading day's close of $34.76.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, operates in the field of dialysis care and dialysis products for the treatment of end-stage renal disease. Fresenius Medical Care AG & Co. KGaA has a market cap of $20.9 billion and is part of the health care sector. The company has a P/E ratio of 18.0, above the S&P 500 P/E ratio of 17.7. Shares are up 1.3% year to date as of the close of trading on Wednesday. Currently there are 2 analysts that rate Fresenius Medical Care AG & Co. KGaA a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Fresenius Medical Care AG & Co. KGaA as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year, good cash flow from operations, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Fresenius Medical Care AG & Co. KGaA Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Brookdale Senior Living ( BKD) is up $0.78 (2.7%) to $29.38 on light volume. Thus far, 287,360 shares of Brookdale Senior Living exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $28.46-$29.39 after having opened the day at $28.62 as compared to the previous trading day's close of $28.60.

Brookdale Senior Living Inc. operates senior living communities in the United States. It offers independent living, assisted living, Alzheimer's and dementia care, rehabilitation and skilled nursing, continuing retirement care, and life care services for residents. Brookdale Senior Living has a market cap of $3.6 billion and is part of the health care sector. Shares are up 12.9% year to date as of the close of trading on Wednesday. Currently there are 4 analysts that rate Brookdale Senior Living a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Brookdale Senior Living as a hold. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and poor profit margins. Get the full Brookdale Senior Living Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Universal Health Services ( UHS) is up $0.55 (0.7%) to $82.76 on light volume. Thus far, 122,806 shares of Universal Health Services exchanged hands as compared to its average daily volume of 702,000 shares. The stock has ranged in price between $82.13-$82.92 after having opened the day at $82.49 as compared to the previous trading day's close of $82.21.

Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, behavioral health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. Universal Health Services has a market cap of $7.5 billion and is part of the health care sector. The company has a P/E ratio of 15.6, below the S&P 500 P/E ratio of 17.7. Shares are up 70.0% year to date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Universal Health Services a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Universal Health Services as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Universal Health Services Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Varian Medical Systems ( VAR) is up $1.60 (2.1%) to $78.29 on average volume. Thus far, 491,099 shares of Varian Medical Systems exchanged hands as compared to its average daily volume of 770,200 shares. The stock has ranged in price between $76.85-$78.41 after having opened the day at $77.01 as compared to the previous trading day's close of $76.69.

Varian Medical Systems, Inc. designs, manufactures, sells, and services medical devices and software for treating cancer with radiotherapy, radiosurgery, proton therapy, and brachytherapy worldwide. Varian Medical Systems has a market cap of $8.1 billion and is part of the health care sector. The company has a P/E ratio of 19.3, above the S&P 500 P/E ratio of 17.7. Shares are up 9.2% year to date as of the close of trading on Wednesday. Currently there are 7 analysts that rate Varian Medical Systems a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Varian Medical Systems as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Varian Medical Systems Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Humana ( HUM) is up $0.59 (0.6%) to $104.37 on light volume. Thus far, 226,250 shares of Humana exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $103.81-$104.47 after having opened the day at $103.81 as compared to the previous trading day's close of $103.78.

Humana Inc., a health care company, offers a range of insurance products, and health and wellness services that incorporate an integrated approach to lifelong well-being. The company operates in three segments: Retail, Employer Group, and Healthcare Services. Humana has a market cap of $16.2 billion and is part of the health care sector. The company has a P/E ratio of 11.4, below the S&P 500 P/E ratio of 17.7. Shares are up 51.2% year to date as of the close of trading on Wednesday. Currently there are 12 analysts that rate Humana a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Humana as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Humana Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists